Acumen PharmaceuticalsABOS
About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Employees: 52
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1% more funds holding
Funds holding: 80 [Q1] → 81 (+1) [Q2]
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
0.28% more ownership
Funds ownership: 72.26% [Q1] → 72.54% (+0.28%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
40% less capital invested
Capital invested by funds: $176M [Q1] → $105M (-$70.3M) [Q2]
65% less call options, than puts
Call options by funds: $737K | Put options by funds: $2.11M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target | 434%upside $15 | Buy Reiterated | 3 Oct 2024 |
UBS Colin Bristow 33% 1-year accuracy 5 / 15 met price target | 114%upside $6 | Buy Maintained | 15 Aug 2024 |
HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target | 434%upside $15 | Buy Reiterated | 14 Aug 2024 |
Citigroup David Hoang 58% 1-year accuracy 11 / 19 met price target | 149%upside $7 | Buy Initiated | 25 Jul 2024 |
Financial journalist opinion
Based on 3 articles about ABOS published over the past 30 days
